BNP Paribas notify of 4.8% shareholding in Galapagos
(Thomson Reuters ONE) -
Mechelen, Belgium; 1 May 2015 - Galapagos NV (Euronext: GLPG) received a
transparency notification from BNP Paribas.
Pursuant to Belgian transparency legislation[1], Galapagos received a
transparency notification on 27 April 2015 from BNP Paribas Investment Partners
SA, BNP Paribas Asset Management SAS, BNP Paribas Investment Partners Belgium
SA, BNP Paribas Investment Partners UK Ltd. and CamGestion SA. BNP Paribas
Investment Partners SA notified that since 22 April 2015, these entities under
its control hold 1,481201 shares, representing 4.8% of the current 30,870,677
outstanding Galapagos shares. This is compared to the 1,538,622 shares reported
in the transparency notice Galapagos received from BNP Paribas on 5 February
2015.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other indications. In
the field of inflammation, AbbVie and Galapagos signed a collaboration agreement
for the development and commercialization of filgotinib. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in Phase 2B
studies in RA and in Phase 2 in Crohn's disease. Galapagos reported good
activity and a favorable safety profile at 12 weeks in both the DARWIN 1 and 2
trials in RA. AbbVie and Galapagos also signed a collaboration agreement in
cystic fibrosis to develop and commercialize molecules that address mutations in
the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and
corrector GLPG2222 is at the pre-clinical candidate stage. GLPG1205, a first-
in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently being
tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients.
GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown
favorable safety in a Phase 1 trial and is expected to enter Phase 2 in
idiopathic pulmonary fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. Further information at: www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir(at)glpg.com
This release may contain forward-looking statements, including, without
limitation, statements concerning anticipated progress, objectives and
expectations regarding the commercial potential of our product candidates,
intended product development, clinical activity timing, and other objectives and
explanations, all of which involve certain risks and uncertainties. These
statements are often, but are not always, made through the use of words or
phrases such as "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," "continues," "we
believe," "we intend," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially different from
any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Among the
factors that may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product development
activities, regulatory approval requirements and estimating the commercial
potential of our product candidates. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication of
this document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
regulation.
--------------------------------------------------------------------------------
[1] Belgian Act of 2 May 2007 on the disclosure of major
shareholdings in issuers whose shares are admitted to trading on a regulated
market)
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1918056]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Lakeland Resources Inc. Reports Uranium Values at the Gibbons Creek Property, Athabasca Basin, Saskatchewan, Canada
Datum: 01.05.2015 - 18:00 Uhr
Sprache: Deutsch
News-ID 390246
Anzahl Zeichen: 5950
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 167 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BNP Paribas notify of 4.8% shareholding in Galapagos"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
